Melissa Hardesty, MD, MPH, Discusses the Focus of the 2021 Society of Gynecologic Oncology Annual Meeting

Article

Hardesty detailed her expectations for the focus of the conference and the exciting topical opportunities presented this year’s SGO Annual Meeting compared with past years.

Melissa Hardesty, MD, MPH, of the Alaska Women’s Cancer Care, spoke with CancerNetwork® regarding topics of discussion at the forefront of this year’s Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer.

Transcription:

This year, the meeting has focused on diversity and inclusiveness [by] really looking at some actual research about how these things impact our patients, how they impact our providers, racial bias, and all of that. There’s a lot of content that’s specifically trying to help us learn how to do better in these ways, to just continue on further conversations. I know that the program organizers have put a strong emphasis on that. There [are] exciting talks in the opening plenary that I think in meetings past might not have been selected for [presentation, and] focusing on the commitment to that area.

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content